A Pharmaceuticals (API and Intermediary Manufacturing) entity from India is looking to sellout.

Posted By - Investment Banker Posted date - 03/08/2022

BUSINESS BRIEF

  • The company is an Intermediates & API manufacturer, operating since 2008.
  •  It has two factories with an overall capacity of over 500 KL.
  • Key Clientele: OLON, MOEHS, KOLON, VALEANT, TEVA, AUROBINDO, MYLAN, SUN PHARMA, SOLARA ACTIVE PHARMA SCIENCES, GLENMARK LIFE SCIENCES, NICHOLAS PIRAMAL and many more.
  • Expertise in handling critical reactions like Cyanation, Hydrogenation, Bromination, Grignard, High vacuum
    distillation, Cryogenic reactions, and more.
  • Complete backward integration and suitable capability to handle both low-volume and high-volume
    products at the commercial level.
  •  In the process of increasing the production capacity by 300 KL. Currently, the company has taken an organic expansion of over 130-150KL of capacity in its Choutuppal unit which is expected to get operationalized during second half of FY22-23.

Key Highlights:

  • Total land extent: 11 Acres+
  • Assets Quality: Best Infrastructure
  • Certification: US FDA approved & others

Expertise:

  • Quality Policy- The company is committed to practicing the best quality standards in research &
    development and manufacturing of pharmaceutical products through periodic review systems.
  • Product Focus- The company is very keen on product selection and commercialization
    based on the market demand for the product and its uniqueness.
  • Spread- One of the core competencies was to reach different customers and markets to understand
    their needs and cater to them aptly.
  • Speed: Well known in the industry for being swift in development, optimization,
    validation and commercialization of new products/projects.
  • R&D: Well-equipped and dedicated Research and Development lab consisting of professional scientists & chemists with strong knowledge of chemistry.
  • Integration: Company's backward integration with their KSM & intermediate manufacturing
    enables cost competence, sustainability, better supply chain control, and strict quality standards
    adherence.

 

Disclaimer: 
-For further information, the promoter requires the signing of an LOI
-Papers & Financials: Ready in place & can be checked at the owner's office only.

Proposal
Icon

Industry

Pharmaceuticals

Icon

Sub Industry

API

Icon

Deal Size

INR 400 - 450 Cr

Icon

Motives For Sellout

Raising Capital

Business Operation Information
Icon

Industry

Pharmaceuticals

Icon

Sub-Industry

API

Icon

Type

Icon

Location

Icon

Major Products

Icon

Major Customers

Financial Information
2019 (in Cr) 2020 (in Cr) 2021 (in Cr) 2022 (in Cr)
Sales
INR 66.1 Cr INR 92.5 Cr INR 113.1 Cr N.D
EBITDA
N.D N.D N.D N.D
PAT
N.D N.D N.D N.D
TOTAL DEBT
N.D N.D N.D N.D
Business Documents